Molecular insights into type I interferon suppression and enhanced pathogenicity by species B human adenoviruses B7

Drayson Graves1, Nikolas Akkerman1, Lauren Fulham1

  • 1Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.

Mbio
|June 28, 2024
PubMed

Insights

Highly pathogenic human adenoviruses (HAdVs) species B, like HAdV-B7 and B14, resist type I interferon by blocking gene expression. These viruses sequester key proteins, hindering the innate immune response and causing severe disease.

Area of Science:

  • Virology
  • Immunology
  • Molecular Biology

Background:

  • Human adenoviruses (HAdVs) are common viruses, but certain species B strains cause severe pneumonia with high mortality.
  • The molecular mechanisms behind the enhanced pathogenicity and innate immune suppression by species B HAdVs remain largely unknown.

Purpose of the Study:

  • To investigate the molecular mechanisms by which species B adenoviruses (HAdV-B7, HAdV-B14) suppress the host interferon signaling pathway.
  • To understand how these viruses evade innate immunity and contribute to severe disease outcomes.

Main Methods:

  • Comparative analysis of HAdV-C2, HAdV-B7, and HAdV-B14 infection in human cells.
  • Assays to measure interferon-stimulated gene expression and protein localization (STAT2, RNA polymerase II, RuvBL1/2).
  • Proteomic analysis to identify host cell protein changes.

Main Results:

  • Species B HAdVs (HAdV-B7, B14) are resistant to type I interferon, unlike HAdV-C2.
  • HAdV-B7 and B14 sequester STAT2 and RNA polymerase II, preventing interferon-stimulated gene activation.
  • RuvBL1 and RuvBL2 cofactors are sequestered in the cytoplasm, impairing gene activation.
  • Proteomic analysis revealed distinct host cell perturbations by different HAdV species.

Conclusions:

  • Species B HAdVs employ efficient strategies to suppress interferon signaling and innate immunity.
  • The sequestration of key cellular factors and cofactor complexes contributes to the high pathogenicity of HAdV-B7 and B14.
  • Understanding these mechanisms provides a foundation for future therapeutic strategies against severe HAdV infections.